You are viewing: US AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The US AI in Oncology Market was valued at $982.1 Million in 2024 and projected to reach to $4498.6 Million by 2029, representing a compound annual growth rate of 28.9%. The US AI in Oncology Market is poised for exceptional growth through 2029, driven by increasing cancer prevalence, demand for precision medicine, and healthcare provider investments in AI-enabled diagnostic and treatment platforms.

US AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US AI in Oncology Market Trends and Insights

  • The US market is driven by advanced healthcare infrastructure, significant R&D investments, and widespread adoption of AI-powered diagnostic and treatment solutions across major oncology centers.
  • The US represents a critical hub for innovation, with leading pharmaceutical companies, healthcare providers, and technology firms accelerating AI integration into cancer detection, prognosis, and personalized treatment planning. Growth in the US market is fueled by increasing cancer incidence, rising demand for precision medicine, and regulatory support for AI-enabled medical devices.
  • The US healthcare system's emphasis on early detection and improved patient outcomes has created substantial opportunities for AI vendors.
  • Between 2024 and 2029, the US market is expected to expand at a compound annual growth rate of 28.9%, reflecting strong clinical validation and reimbursement pathways for AI oncology solutions. The US competitive landscape includes established medical device manufacturers, emerging AI startups, and technology giants investing heavily in oncology applications.
  • Partnerships between healthcare institutions and AI developers are accelerating market penetration, while FDA approvals and clinical evidence continue to build confidence in AI-driven oncology tools across the US healthcare ecosystem..

Key Market Statistics

  • CAGR (2024-2029) 28.9% CAGR
  • Market Size, 2024 ~USD 982.1 Million
  • Forecast, 2029 ~USD 4498.6 Million
  • Country US

US AI in Oncology Market Overview

Market Valuation Growth :

The US AI in Oncology Market is valued at $982.1 million in 2024, with a robust CAGR of 28.9%, projected to reach $4,498.6 million by 2029, representing a 358% increase over five years.

Advanced Healthcare Infrastructure :

The US benefits from world-class healthcare systems, cutting-edge medical facilities, and established digital health ecosystems that accelerate AI adoption in oncology centers across the nation.

R&D Investment Leadership :

Significant government and private sector R&D investments in the US drive innovation in AI-powered diagnostic imaging, treatment planning, and personalized oncology solutions.

Innovation Hub Status :

Leading US oncology centers, biotech companies, and tech firms collaborate to develop and deploy AI solutions, positioning the country as the global epicenter for oncology AI innovation.

US AI in Oncology Market Dynamics

  • Major oncology institutions are rapidly integrating AI tools for pathology analysis, treatment optimization, and patient outcome prediction.
  • Regulatory support and reimbursement pathways are strengthening, encouraging broader adoption across hospital networks and specialized cancer centers.
  • The competitive landscape features both established healthcare IT companies and innovative startups developing next-generation solutions.
  • Continued investment in clinical validation and real-world evidence will further accelerate market penetration and establish AI as standard-of-care in US oncology practices..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • The US AI in Oncology Market is valued at $982.1 million in 2024 and is forecast to grow to $4,498.6 million by 2029, representing a 28.9% CAGR.
      • The US market benefits from advanced healthcare infrastructure, robust regulatory frameworks, and strong reimbursement models that support AI adoption in oncology.
      • Precision medicine and early cancer detection are primary growth drivers in the US, with AI solutions increasingly integrated into diagnostic workflows.
      • The US competitive landscape is characterized by partnerships between healthcare institutions, technology companies, and pharmaceutical firms accelerating AI oncology innovation.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      US AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      US: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030

      Segment202220232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTIONS60.780.1101.8129.8166213274.1353.8458.128.5
      GOVERNMENT & REGULATORY AGENCIES23.730.838.648.561.277.498.2125159.626.7
      HEALTHCARE PAYERS16.72227.835.34557.473.694.6122.128
      HEALTHCARE PROVIDERS277.7369.4473.3608.2784.11013.91315.11711.32233.729.5
      MEDICAL DEVICE/ EQUIPMENT COMPANIES52.568.686.3108.9137.8175.1223285365.327.2
      OTHER END USERS11.214.618.423.12936.545.957.772.525.7
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES139.5184.9235.9302387.8499.4645.3836.31087.229
      TOTAL582770.4982.11255.91610.92072.62675.23463.84498.628.9

      Target Audience

      • Healthcare IT Companies : Evaluate market expansion opportunities in US oncology AI, assess competitive positioning, and identify acquisition or partnership targets to accelerate growth in this high-CAGR segment.
      • Oncology Center Executives : Understand AI solution adoption trends across US cancer centers, benchmark technology investments against peers, and make informed procurement decisions for diagnostic and treatment platforms.
      • Venture Capital & Private Equity : Identify promising AI oncology startups and investment opportunities in the US market, assess market size and growth potential, and evaluate exit opportunities in this rapidly expanding sector.
      • Pharmaceutical & Biotech Companies : Leverage AI market insights to enhance drug development, clinical trial design, and patient stratification strategies, while identifying partnership opportunities with leading US AI vendors.
      • Healthcare Consultants & Analysts : Access comprehensive US market data to support client advisory work, competitive analysis, and strategic planning in oncology AI, with detailed forecasts and market trend analysis.

      Reasons to Buy this Report

      • Strategic Market Sizing : Obtain precise valuation data for the US market ($982.1M in 2024) with detailed forecasts through 2029, enabling accurate budget allocation and investment planning for oncology AI initiatives.
      • Competitive Intelligence : Identify leading US oncology centers, healthcare systems, and AI vendors driving market adoption, understand their strategies, and benchmark your positioning against key competitors.
      • Growth Opportunity Assessment : Leverage the 28.9% CAGR insight to identify high-growth segments within US oncology AI, including diagnostic imaging, treatment planning, and clinical decision support systems.
      • Regulatory & Reimbursement Insights : Understand US-specific regulatory pathways, FDA approval trends, and insurance reimbursement models that directly impact market adoption and revenue potential for AI oncology solutions.
      • Investment Decision Support : Make informed decisions on market entry, partnerships, or acquisitions in the US oncology AI space with comprehensive data on market dynamics, barriers to entry, and growth catalysts.

      Frequently asked questions

      What is the current size of the US AI in Oncology Market?

      The US AI in Oncology Market was valued at $982.1 million in 2024 and is projected to reach $4,498.6 million by 2029.

      What is the expected growth rate for the US AI in Oncology Market?

      The US market is expected to grow at a compound annual growth rate (CAGR) of 28.9% from 2024 to 2029.

      What are the primary drivers of growth in the US AI in Oncology Market?

      Key drivers include increasing cancer incidence, demand for precision medicine, FDA regulatory support, advanced healthcare infrastructure, and strong reimbursement pathways in the US.

      Which applications are leading AI adoption in US oncology?

      The US market is seeing significant adoption in diagnostic imaging analysis, treatment planning, prognosis prediction, and personalized medicine applications.

      Who are the major players in the US AI in Oncology Market?

      The US market includes established medical device manufacturers, emerging AI startups, technology giants, and healthcare institutions collaborating to advance AI oncology solutions.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status